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Structurally optimised BODIPY derivatives for
imaging of mitochondrial dysfunction in cancer
and heart cells†
Shubhanchi Nigam,ab Benjamin P. Burke,ab Laura H. Davies,c Juozas Domarkas,bd
Jennifer F. Wallis,c Paul G. Waddell,c Jennifer S. Waby,e David M. Benoit,a
Anne-Marie Seymour,de Christopher Cawthorne,be Lee J. Higham*c and
Stephen J. Archibald*ab
The structural features required for mitochondrial uptake of BODIPY-
based optical imaging agents have been explored. The first derivatives
of this class of dyes shown to have mitochondrial membrane
potential-dependent uptake in both cancer and heart cells have
been developed.
Mitochondrial membrane potential (MMP) plays a key role in
cardiac failure and cancer.1 The electron transport chain con-
tained within the impermeable inner mitochondrial membrane
gives rise to a negative membrane potential (ca. 150 mV to
170 mV) in healthy cells.2,3 In cancerous and ischaemic heart
cells, mitochondrial dysfunction can substantially disrupt the
MMP4,5 resulting in up to a tenfold increase in accumulation of
MMP-dependent compounds.2,3 During apoptotic or necrotic cell
death, complete membrane depolarisation occurs and no uptake
is observed.6,7 Lipophilic cations carrying a positive charge can
pass through lipid bilayers in the mitochondria and accumulate
proportionally to the change in membrane potential gradient.2
Optical agents have been developed for MMP-dependent imaging,
with many derivatives based on rhodamine and tetramethylros-
amine structures, with the highly eﬀective Mitotrackers series
now in common use.2,8
Boron-dipyrromethene (BODIPY) type structures are regu-
larly used in optical biomedical imaging due to their tunable
wavelength emission, photostability, remarkable brightness and
biological media compatibility.9–12 Recently, the use of BODIPYs
has been further extended by the incorporation of the positron
emitting radioisotope, fluorine-18, resulting in multimodal positron
emission tomography (PET)/optical imaging agents.13–15 Formation
of BODIPY based PET/optical multimodal imaging can be achieved
via B–F bond formation or modification of the structural backbone
to incorporate the radiolabel.
To date, there have been no reports of BODIPY-based agents
capable of imaging both cancer and heart cells in a MMP-
dependent manner. Phosphonium-based lipophilic cations have
been receiving interest, most notably in the development of PET
imaging agents.16–21 Recently, Yuan et al. described a BODIPY
triphenylphosphonium-based lipophilic cation designed for
multimodal imaging which did not show MMP-dependent mito-
chondrial uptake.20 The development of MMP-dependent tracers
would offer the capability for detection of mitochondrial dys-
function in cardiac disease and cancer together with the potential
for monitoring of therapeutic responses.
Our approach in designing MMP dependent BODIPY deriva-
tives is to form phosphonium cations directly on the lipophilic
BODIPY backbone and study their chemical and biological
characteristics. We have previously developed highly fluorescent,
air-stable BODIPY-based phosphanes22 carrying either dicyclohexyl
and diphenyl substituents.23 Methylation with methyl trifluoro-
methanesulfonate gave phosphonium derivatives 1 and 2 (see
Fig. 1 and ESI†).
Mitochondrial uptake studies of 1 and 2 were carried out using
confocal microscopy in human breast cancer cells (MCF-7) and rat
cardiomyocytes (H9c2).Mitotracker deep red (MDR) was used for dye
co-localisation studies as its emission wavelength (665 nm) is suﬃci-
ently diﬀerent from that of 1 and 2 (532 nm) to allow independent
detection. Confocal microscopy confirmed mitochondrial localisa-
tion of both 1 and 2 (see Fig. 2 and ESI† for further details). Overlap
coeﬃcients identified that both tracers showed similarly high
mitochondrial localisation in H9c2 cells, however the overlap coeﬃ-
cient was 36% higher in MCF-7 cells for 1, indicating that it has
significantly greater potential as a specific imaging agent.
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Imaging agents with MMP-dependent uptake oﬀer an ideal
tool to probe mitochondrial function. To establish the mito-
chondrial membrane potential specific uptake of 1 and 2, a
flow cytometry study was carried out in the presence of carbonyl
cyanide m-chlorophenylhydrazone (CCCP), a protonophore
which eliminates the mitochondrial membrane potential (see
Fig. 3 and ESI† for further details).24,25 Both tracers showed a
decrease in mean fluorescent intensity (MFI) upon CCCP
induced MMP depolarisation in both cell lines. 1 showed a
greater than 70% decrease inMCF-7 and H9c2 cell lines, whereas
2 showed a smaller 38% and 58% decrease in MCF-7 and H9c2
cells respectively.
The vastmajority of lipophilic cations used inmolecular imaging
are based on triphenylphosphonium ions.3,16,18,19 In this study,
we have designed and synthesised a triphenylphosphonium
BODIPY structure (2) along with a cyclohexyl derivative (1) to
explore the structural features necessary for MMP-dependent
uptake. Both the mitochondrial localisation determined by
confocal microscopy and the flow cytometry MMP-dependent
uptake studies demonstrate that the replacement of two phenyl
groups for two cyclohexyl groups cause an increase in MMP
dependent, mitochondrial specific uptake. DFT calculations
were carried out on both structures to determine the degree
of delocalisation of electron density. Our calculations show (see
Fig. 4 and ESI† for further details) that the charge is localised
on the phosphorus atom for the cyclohexyl derivative (1) while it
is mainly delocalised on the aromatic ligands for the triphenyl-
phosphonium structure (2). The eﬀect of the degree of lipo-
philicity on the uptake of lipophilic cations has been partially
explored in previous studies, generally when describing selec-
tivity between cancer and cardiac uptake.16 The lipophilicity
(log P) values of 1 and 2 were determined to be 3.19 and 2.80
respectively, revealing a significant increase in lipophilicity for
the cyclohexyl derivative.
To validate the strategy and open opportunities for future
PET/optical imaging agents, we have replaced methyl trifluoro-
methanesulfonate in the final step methylation reaction of
the dicyclohexyl derivative with 1-bromo-4-fluorobutane. The
structure of the formed product, 3, was confirmed by NMR and
X-ray crystallography (see ESI†) and is the cold standard of a
potential future radiolabelled product. The fluorine-18 analogue
can be prepared via conventional nucleophilic substitution in a
one step procedure or directly from 1 in a 2-step radiolabelling
protocol.26,27
Flow cytometry studies on 3, carried out using an identical
protocol to that used to analyse 1 and 2, demonstrated that this
fluoride substituted derivative behaves in an analogous fashion.
Fig. 3 Flow cytometry studies of 1 and 2 in MCF-7 (left) and H9c2 (right) cells
without (green) and with (pink) the presence of mitochondrial membrane
depolarising agent (CCCP) to assess mitochondrial membrane potential uptake.
Fig. 1 Chemical structures of phosphonium BODIPY derivatives 1 and 2.
Fig. 2 Confocal microscopy of 1 and 2 (left) in MCF-7 and H9c2 cell
lines with mitotracker deep red (MDR, centre), overlaid mitochondrial
co-localisation (right).
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Replacement of the methyl group in 1 with a fluorobutyl leads
to an increase in MMP dependent uptake, with CCCP causing
decreases in uptake of 84% and 83% in MCF-7 and H9c2 cells
respectively (see Fig. 5), thus validating this approach for the
design of multimodal optical/PET imaging agents.
In conclusion, we have developed novel BODIPY based agents
for mitochondrial imaging. These agents, for the first time, have
been shown to be taken up in mitochondria in a mitochondrial
membrane potential-dependent manner in both cancer and heart
cells. The new structural class, with the phosphonium grafted
directly on the BODIPY backbone, oﬀers the opportunity to reduce
non-specific binding by optimising the lipophilicity of a dicyclo-
hexyl derviative with shielded localised charge. This work validates
the structural features required to develop MMP-dependent PET/
optical multimodal imaging via fluorine-18 radiolabelling. Studies
are currently underway to develop these agents for in vivo use.
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